Pfizer/Ligand Fablyn delayed
Executive Summary
FDA issues "complete response" letter for Pfizer/Ligand's osteoporosis drug Fablyn (lasofoxifene) Jan. 16. FDA has expressed concern with an apparent increase in mortality among Fablyn patients. FDA's Reproductive Health Drugs Advisory Committee found that trend to be inconclusive during a Sept. 8 meeting, and voted 9-3 (with one abstention) that there was a population of post-menopausal women with osteoporosis for which the use of Fablyn outweighed the risks (1"The Pink Sheet," Sept. 15, 2008, p. 3). Pfizer proposed a 50,000-patient post-marketing safety cohort study to help resolve the issue
You may also be interested in...
Fablyn Panel Finds Mortality Trend Inconclusive, But Pfizer Ready With A Plan
FDA's Advisory Committee for Reproductive Health Drugs did not reach a clear conclusion on whether Pfizer's osteoporosis drug Fablyn has a mortality issue - but Pfizer already has a proposal for a post-market study to provide a definitive answer
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.